Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Immunol ; 40(3): 803-12, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20017192

ABSTRACT

We have shown previously that cytokines IL-4 and IL-13 induce protection in porcine vascular endothelial cells (EC) against killing by the membrane attack complex (MAC) of human complement. This protection is intrinsic, not due to changes in complement regulatory proteins, and requires activation of Akt and sterol receptor element binding protein-1 (SREBP-1), which regulates fatty acid and phospholipid synthesis. Here we report that, compared to EC incubated in medium, IL-4-treated EC had a profound reduction in complement-mediated ATP loss and in killing assessed by vital dye uptake, but only a slight reduction in permeability disruption measured by calcein release. While controls exposed to complement lost mitochondrial membrane potential and subsequently died, protected EC maintained mitochondrial morphology and membrane potential, and remained alive. SREBP-1 and fatty acid synthase activation were required for protection and fatty acid and phospholipid synthesis, including cardiolipin, were increased after IL-4 stimulation, without increase in cholesterol content or cell proliferation. IL-4 also induced protection of EC from killing by the channel forming protein melittin, similar to protection observed for the MAC. We conclude that IL-4 induced activation of Akt/SREBP-1/lipid biosynthesis in EC, resulting in protection against MAC and melittin, in association with mitochondrial protection.


Subject(s)
Complement System Proteins/drug effects , Endothelial Cells/drug effects , Interleukin-4/pharmacology , Lipids/biosynthesis , Melitten/adverse effects , Signal Transduction/drug effects , Animals , Blotting, Western , Cell Membrane Permeability , Cell Separation , Complement Membrane Attack Complex/drug effects , Endothelial Cells/metabolism , Endothelial Cells/ultrastructure , Flow Cytometry , Interleukin-4/metabolism , Membrane Potential, Mitochondrial/drug effects , Microscopy, Electron, Transmission , Mitochondria/pathology , Proto-Oncogene Proteins c-akt/drug effects , Proto-Oncogene Proteins c-akt/metabolism , Sterol Regulatory Element Binding Protein 1/drug effects , Sterol Regulatory Element Binding Protein 1/metabolism , Swine
2.
J Immunol ; 177(10): 7355-63, 2006 Nov 15.
Article in English | MEDLINE | ID: mdl-17082655

ABSTRACT

Vascular endothelial cells (ECs) can be injured in a variety of pathologic processes that involve activated complement. We reported previously that porcine ECs incubated with exogenous IL-4 or IL-13 are protected from cytotoxicity by human complement and also from apoptosis by TNF-alpha. The resistance to complement consists of an intrinsic mechanism that is lost a few days after cytokine removal. In our current study, we investigated whether transfer of the IL-4 gene into porcine ECs in vitro and into porcine vascular tissues in vivo would induce efficient and durable protection from human complement. We found that ECs transduced with adenoIL-4 or adenoIL-13 exhibited continuous production of the cytokine and prolonged protection from complement-mediated killing. IL-4 also protected ECs from activation: ECs incubated with IL-4 did not develop cell retraction and intercellular gaps upon stimulation with sublytic complement. The endothelium and subendothelium of pig iliac arteries that were transduced with the IL-4 gene were effectively protected from complement-dependent immediate injury after perfusion with human blood. However, after similar perfusion, the endothelium was immediately lost from arteries that were transduced with a control adenovirus. The protection was not due to up-regulation of the complement regulators decay accelerating factor, membrane cofactor protein, and CD59, or to reduced complement activation, but required the participation of Akt. Although our studies model protection in pig-to-primate xenotransplantation, our findings of IL-4 induction of Akt-mediated protection may be more broadly applicable to EC injury as manifested in ischemia-reperfusion, allotransplantation, and various vascular diseases.


Subject(s)
Complement System Proteins/toxicity , Endothelium, Vascular/immunology , Endothelium, Vascular/metabolism , Iliac Artery/immunology , Iliac Artery/metabolism , Interleukin-4/genetics , Proto-Oncogene Proteins c-akt/metabolism , Transduction, Genetic , Adenoviridae/genetics , Animals , Blood/immunology , Cells, Cultured , Complement System Proteins/metabolism , Cytotoxicity, Immunologic/genetics , Endothelium, Vascular/cytology , Extracellular Fluid/immunology , Extracellular Fluid/metabolism , Gene Transfer Techniques , Humans , Iliac Artery/cytology , Immunity, Innate/genetics , Interleukin-13/biosynthesis , Interleukin-13/genetics , Interleukin-4/biosynthesis , Interleukin-4/physiology , Perfusion , Proto-Oncogene Proteins c-akt/physiology , Swine
3.
J Immunol ; 175(3): 1903-10, 2005 Aug 01.
Article in English | MEDLINE | ID: mdl-16034134

ABSTRACT

Vascular endothelial cells (EC) perform critical functions that require a balance of cell survival and cell death. EC death by apoptosis and EC activation and injury by the membrane attack complex of complement are important mechanisms in atherosclerosis and organ graft rejection. Although the effects of various cytokines on EC apoptosis have been studied, little is known about their effects on complement-mediated EC injury. Therefore, we studied the abilities of various cytokines to induce protection of porcine aortic EC against apoptosis and killing by human complement, a model of pig-to-human xenotransplantation. We found that porcine EC incubated with IL-4 or IL-13, but not with IL-10 or IL-11, became protected from killing by complement and apoptosis induced by TNF-alpha plus cycloheximide. Maximal protection required 10 ng/ml IL-4 or IL-13, developed progressively from 12 to 72 h of incubation, and lasted 48-72 h after cytokine removal. Protection from complement was not associated with reduced complement activation, C9 binding, or changes in CD59 expression. Inhibition of PI3K prevented development of protection; however, inhibition of p38 MAPK or p42/44 MAPK had no effect. IL-4 and IL-13 induced rapid phosphorylation of Akt. Although protection was inhibited by an Akt inhibitor and a dominant negative Akt mutant transduced into EC, it was induced by transduction of EC with the constitutively active Akt variant, myristylated Akt. We conclude that IL-4 and IL-13 can induce protection of porcine EC against killing by apoptosis and human complement through activation of the PI3K/Akt signaling pathway.


Subject(s)
Apoptosis/immunology , Complement Activation/immunology , Cytotoxicity, Immunologic/immunology , Endothelium, Vascular/immunology , Interleukin-13/physiology , Interleukin-4/physiology , Phosphatidylinositol 3-Kinases/physiology , Protein Serine-Threonine Kinases/physiology , Proto-Oncogene Proteins/physiology , Animals , CD59 Antigens/biosynthesis , Cells, Cultured , Complement C9/metabolism , Cycloheximide/antagonists & inhibitors , Cycloheximide/toxicity , Endothelium, Vascular/enzymology , Endothelium, Vascular/metabolism , Endothelium, Vascular/pathology , Humans , MAP Kinase Signaling System/immunology , Necrosis , Phosphorylation , Protein Binding/immunology , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt , Swine , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/toxicity
4.
Am J Physiol Endocrinol Metab ; 289(5): E883-91, 2005 Nov.
Article in English | MEDLINE | ID: mdl-15972274

ABSTRACT

A quantitative analysis of zone-specific proliferation was done to determine the recovery of adrenal cortical zonation during regeneration after enucleation. Adult male rats underwent adrenal enucleation [unilateral enucleation (ULE)] or sham surgery, both accompanied by contralateral adrenalectomy. At 2, 5, 10, and 28 days, blood and adrenals were collected to assess functional recovery. Adrenal sections were immunostained for Ki67 (proliferation), cytochrome P-450 aldosterone synthase (P-450aldo, glomerulosa), and cytochrome P-450 11beta-hydroxylase (P-45011beta, fasciculata). Unbiased stereology was used to count proliferating glomerulosa and fasciculata cells. Recovery of fasciculata secretory function occurred by 28 days as reflected by plasma ACTH and corticosterone, whereas glomerulosa function reflected by plasma aldosterone remained low at 28 days. At 5 days, ULE adrenals showed increased Ki67+ cells in the glomerulosa and inner fasciculata, whereas at 10 and 28 days increased proliferation was restricted to the outer fasciculata. These data show that enucleation results in transient elevations in glomerulosa and inner fasciculata cell proliferation followed by a delayed increase in the outer fasciculata. To assess adrenal growth in enucleated adrenals previously suppressed by the presence of an intact adrenal, rats underwent ULE and sham surgery; after 4 wk, the intact adrenal was removed and enucleated adrenals were collected at 2, 5, and 10 days. Overall, proliferation was delayed in this model, but at 5 days, Ki67+ cells increased in the outer fasciculata, whereas by 10 days, increased proliferation occurred in the outer and inner fasciculata. The key novel finding of increased proliferation in the inner fasciculata suggests that the delayed growth of the enucleated adrenal results in part from a regenerative response.


Subject(s)
Adrenal Cortex/physiology , Regeneration/physiology , Zona Fasciculata/physiology , Zona Glomerulosa/physiology , Adrenal Cortex/cytology , Adrenal Cortex/enzymology , Adrenal Cortex/surgery , Adrenocorticotropic Hormone/blood , Aldosterone/blood , Animals , Cell Growth Processes/physiology , Corticosterone/blood , Cytochrome P-450 CYP11B2/metabolism , Fluorescent Antibody Technique , Histocytochemistry , Ki-67 Antigen/metabolism , Male , Rats , Rats, Sprague-Dawley , Steroid 11-beta-Hydroxylase , Zona Fasciculata/enzymology , Zona Glomerulosa/enzymology
5.
Wound Repair Regen ; 13(2): 165-74, 2005.
Article in English | MEDLINE | ID: mdl-15828941

ABSTRACT

Opioids are sometimes used to treat pain in ulcerative wounds, and it is speculated that pain interferes with the healing process. Because the direct effect of opioids on this process remains unknown, we examined the effect of topically applied opioids on the healing of open ischemic wounds in rats. Topically applied opioids hastened wound closure, particularly in the first 4 days when no healing was initiated in phosphate buffered saline solution-treated wounds. After 1 week of application, fentanyl, hydromorphone, and morphine resulted in 66%, 55%, and 42% wound closure, respectively, as compared to only 15% in control wounds. Opioid-induced healing was accompanied by a 1.5- to 2.5-fold increase in nuclear density in the granulation tissue and 45-87% increase in angiogenesis as compared to phosphate buffered saline solution-treated wounds. Fentanyl showed significantly improved healing compared to morphine and hydromorphone (p < 0.05, fentanyl vs. others). Fentanyl-induced healing was inhibited by the opioid receptor antagonist naloxone, suggesting that peripheral opioid receptor(s) mediate the healing process. Opioids accelerate healing by up-regulating both endothelial and inducible nitric oxide synthase and the vascular endothelial-derived growth factor receptor Flk1 in the wounds. We envision that opioids can be used topically to accelerate wound healing in diverse clinical conditions ranging from surgical incisions to nonhealing ischemic ulcers in pathophysiological conditions and in hospice patients.


Subject(s)
Analgesics, Opioid/administration & dosage , Fentanyl/administration & dosage , Ischemia/complications , Wound Healing/drug effects , Wounds and Injuries/drug therapy , Administration, Topical , Analgesics, Opioid/pharmacology , Animals , Cell Proliferation/drug effects , Fentanyl/pharmacology , Granulation Tissue/drug effects , Hydromorphone/administration & dosage , Hydromorphone/pharmacology , Morphine/administration & dosage , Morphine/pharmacology , Neovascularization, Physiologic/drug effects , Rats , Skin/drug effects , Skin/physiopathology , Wounds and Injuries/complications , Wounds and Injuries/physiopathology
6.
Am J Transplant ; 5(4 Pt 1): 712-9, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15760394

ABSTRACT

Cytoprotection of endothelial cells (EC) is important in EC biology and pathophysiology, including graft rejection. Using porcine aortic EC and human complement as an in vitro model of xenotransplantation, we have reported that ligation of EC Gal alpha (1-3)Gal epitopes (alpha Gal) with antibodies or lectins BS-I and IB4 induces EC resistance to injury by complement. However, before the protective response is observed, alpha Gal ligation induces an early, proinflammatory response. Using a similar model, we now investigated whether the early inflammatory response, as well as NF-kappa B activation, is required for induction of cytoprotection. Despite up-regulation of EC mRNA for many inflammatory cytokines rapidly after BS-I stimulation, recombinant cytokines or conditioned media from EC incubated with BS-I failed to induce protection when used to stimulate EC. While the lectin-induced inflammatory response was markedly reduced by inhibition of NF-kappa B, the protection from complement and apoptosis was unaffected. The lectins caused up-regulation of mRNA for protective genes A20, porcine inhibitor of apoptosis protein and hemoxygenase-1, which was not modified by NF-kappa B inhibition. These findings suggest that induction of cytoprotection in porcine EC by alpha Gal ligation results from activation of pathways that are largely independent of those that elicit NF-kappaB activation and the inflammatory response.


Subject(s)
Apoptosis/physiology , Complement System Proteins/metabolism , Disaccharides/metabolism , Endothelial Cells/metabolism , NF-kappa B/metabolism , Animals , Heme Oxygenase (Decyclizing)/metabolism , Heme Oxygenase-1 , Inflammation/metabolism , Inhibitor of Apoptosis Proteins , Proteins/metabolism , Swine , Time Factors
7.
Transplantation ; 77(10): 1500-6, 2004 May 27.
Article in English | MEDLINE | ID: mdl-15239611

ABSTRACT

BACKGROUND: In a pig model of intestinal transplantation, we previously showed that hepatic conditioning through portal donor-specific blood transfusion (pDSBT), high-dose tacrolimus (TAC), and steroids prevented rejection and increased survival Our current study tests a protocol of pDSBT, short-term mycophenolate mofetil (MMF), and low-dose TAC to eliminate the use of steroids, reduce TAC dosage, and increase the level of chimerism in the peripheral blood. MATERIALS AND METHODS: Four groups of outbred, mixed lymphocyte culture (MLC)-reactive pigs underwent bowel transplants and pDSBT. Immunosuppression (group 1, high-dose TAC and steroids; group 2, low-dose TAC and MMF; group 3, low-dose TAC, MMF, and aminoguanidine; group 4, low-dose TAC, MMF, and arginine) was discontinued after 28 days. RNA was extracted from intestinal graft and native liver biopsies for cytokine measurements. Chimerism levels were determined using a Q-PCR analysis. RESULTS: Pig survival and death rates due to rejection did not significantly differ between the four groups. Chimerism levels determined by Q-PCR analysis were not different until day 28. After discontinuation of immunosuppression, we noted a trend (P = 0.15) toward higher mean chimerism levels on day 60 for groups 2, 3, and 4 (9%) vs. group 1 (0.5%). Tissue cytokine and serum nitrate levels did not significantly differ between the four groups. Attempts to modify nitric oxide synthase activity offered no added benefit. CONCLUSIONS: The combination of pDSBT, MMF, and low-dose TAC (vs. high-dose TAC and steroids) allowed sustained levels of mixed chimerism to develop after discontinuation of immunosuppression.


Subject(s)
Blood Transfusion , Immunosuppressive Agents/administration & dosage , Intestines/transplantation , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/administration & dosage , Portal System , Tacrolimus/administration & dosage , Tissue Donors , Transplantation Chimera , Animals , Cytokines/metabolism , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Graft Rejection/mortality , Graft vs Host Disease/mortality , Infections/mortality , Male , Nitric Oxide/metabolism , Steroids/administration & dosage , Survival Analysis , Swine
SELECTION OF CITATIONS
SEARCH DETAIL
...